$PAXH
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.

2023 Q4 Form 10-Q Financial Statement

#000126246323000148 Filed on December 29, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2022 Q4
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $42.93K $43.52K
YoY Change -1.36% 4.09%
% of Gross Profit
Research & Development $2.179K $1.573K
YoY Change 38.53% -24.01%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $45.11K $45.09K
YoY Change 0.04% 2.74%
Operating Profit -$45.11K -$45.09K
YoY Change 0.04% 3.29%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$45.11K -$45.09K
YoY Change 0.04% 3.28%
Income Tax
% Of Pretax Income
Net Earnings -$45.11K -$45.09K
YoY Change 0.04% 3.28%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 19.77M shares 19.77M shares
Diluted Shares Outstanding 19.77M shares 19.77M shares

Balance Sheet

Concept 2023 Q4 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.870K $180.00
YoY Change 938.89% 63.64%
Cash & Equivalents $1.868K $175.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.868K $175.00
YoY Change 967.43% 59.09%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.868K $175.00
Total Long-Term Assets $0.00 $0.00
Total Assets $1.868K $175.00
YoY Change 967.43% 59.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $460.7K $338.1K
YoY Change 36.24% -47.84%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.717M $1.699M
YoY Change 1.08% 40.72%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.385M $2.223M
YoY Change 7.27% 8.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.385M $2.223M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.385M $2.223M
YoY Change 7.27% 8.7%
SHAREHOLDERS EQUITY
Retained Earnings -$5.115M -$4.955M
YoY Change 3.23%
Common Stock $19.77K $19.77K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.383M -$2.223M
YoY Change
Total Liabilities & Shareholders Equity $1.868K $175.00
YoY Change 967.43% 59.09%

Cashflow Statement

Concept 2023 Q4 2022 Q4
OPERATING ACTIVITIES
Net Income -$45.11K -$45.09K
YoY Change 0.04% 3.28%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.11K -$10.72K
YoY Change -5.69% -46.29%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.62K 10.70K
YoY Change 8.6% -46.69%
NET CHANGE
Cash From Operating Activities -10.11K -10.72K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 11.62K 10.70K
Net Change In Cash 1.510K -20.00
YoY Change -7650.0% -118.18%
FREE CASH FLOW
Cash From Operating Activities -$10.11K -$10.72K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Registrant Name
EntityRegistrantName
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001350156
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-11-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-52365
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4395271
dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 34075 Westbrook PO
dei Entity Address Address Line2
EntityAddressAddressLine2
1610-37th Street S.W
dei Entity Address City Or Town
EntityAddressCityOrTown
Calgary
dei Entity Address State Or Province
EntityAddressStateOrProvince
AB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
T3C 3W2
dei City Area Code
CityAreaCode
403
dei Local Phone Number
LocalPhoneNumber
850-4120
dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19767698 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1868 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1868 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
6 usd
CY2023Q4 us-gaap Assets
Assets
1868 usd
CY2023Q2 us-gaap Assets
Assets
6 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
160671 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
158348 usd
CY2023Q4 paxh Accounts Payable And Accrued Liabilities Related Party
AccountsPayableAndAccruedLiabilitiesRelatedParty
300000 usd
CY2023Q2 paxh Accounts Payable And Accrued Liabilities Related Party
AccountsPayableAndAccruedLiabilitiesRelatedParty
240000 usd
CY2023Q4 paxh Due To Related Party Current
DueToRelatedPartyCurrent
72257 usd
CY2023Q2 paxh Due To Related Party Current
DueToRelatedPartyCurrent
64952 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
191329 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
173067 usd
CY2023Q4 paxh Liability For Unissued Shares Current
LiabilityForUnissuedSharesCurrent
134792 usd
CY2023Q2 paxh Liability For Unissued Shares Current
LiabilityForUnissuedSharesCurrent
134792 usd
CY2023Q4 paxh Promissory Note Related Party
PromissoryNoteRelatedParty
466817 usd
CY2023Q2 paxh Promissory Note Related Party
PromissoryNoteRelatedParty
466817 usd
CY2023Q4 paxh Convertible Note Payable Related Party
ConvertibleNotePayableRelatedParty
1058760 usd
CY2023Q2 paxh Convertible Note Payable Related Party
ConvertibleNotePayableRelatedParty
1058760 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2384626 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2296736 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2384626 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2296736 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5114959 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5028931 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2382758 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2296730 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1868 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6 usd
CY2023Q4 us-gaap Revenues
Revenues
0 usd
CY2022Q4 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q4 paxh Consulting Fees
ConsultingFees
30000 usd
CY2022Q4 paxh Consulting Fees
ConsultingFees
30000 usd
paxh Consulting Fees
ConsultingFees
60000 usd
paxh Consulting Fees
ConsultingFees
60000 usd
CY2023Q4 us-gaap Professional Fees
ProfessionalFees
4437 usd
CY2022Q4 us-gaap Professional Fees
ProfessionalFees
7040 usd
us-gaap Professional Fees
ProfessionalFees
12151 usd
us-gaap Professional Fees
ProfessionalFees
9540 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8493 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6479 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10177 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8055 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2179 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1573 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3700 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4844 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
45109 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
45092 usd
us-gaap Operating Expenses
OperatingExpenses
86028 usd
us-gaap Operating Expenses
OperatingExpenses
82439 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-45109 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-45092 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-86028 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-82439 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-45109 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-45092 usd
us-gaap Net Income Loss
NetIncomeLoss
-86028 usd
us-gaap Net Income Loss
NetIncomeLoss
-82439 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19767698 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19767698 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19767698 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19767698 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2337649 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-45109 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2382758 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2296730 usd
us-gaap Net Income Loss
NetIncomeLoss
-86028 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2382758 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2177811 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-45092 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2222903 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-2140464 usd
us-gaap Net Income Loss
NetIncomeLoss
-82439 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2222903 usd
us-gaap Net Income Loss
NetIncomeLoss
-86028 usd
us-gaap Net Income Loss
NetIncomeLoss
-82439 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
60000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
60000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2323 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1572 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23705 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24011 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
18262 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
4992 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
8816 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
19241 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1511 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
306 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25567 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23927 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1862 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-84 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1868 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Profit Loss
ProfitLoss
-86028 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23705 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2382758 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zaISjl6XTf1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_865_zIKf10DKQSR3">Use of Estimates</span> </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p>
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3700 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4844 usd
CY2023Q4 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2022Q4 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
paxh Commissions Percentage
CommissionsPercentage
0.10 pure
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares

Files In Submission

Name View Source Status
paxh-20231130_pre.xml Edgar Link unprocessable
0001262463-23-000148-index-headers.html Edgar Link pending
0001262463-23-000148-index.html Edgar Link pending
0001262463-23-000148.txt Edgar Link pending
0001262463-23-000148-xbrl.zip Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
paxh-20231130.xsd Edgar Link pending
paxh10q113023.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
paxh-20231130_cal.xml Edgar Link unprocessable
paxh-20231130_def.xml Edgar Link unprocessable
paxh-20231130_lab.xml Edgar Link unprocessable
paxh10q113023_htm.xml Edgar Link completed
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending